UNSPSC 51351908: Norgestrienone

This classification denotes a therapeutic estrogen with the molecular formula C20H22O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89386PYU9O, chemically known as 19-norpregna-4,9,11-trien-20-yn-3-one, 17-hydroxy-, (17-alpha)- (9ci) but generally known as norgestrienone, which bears US NIH Compound Identifier 13313. European Medicines Agency schedules Norgestrienone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09372MIG.

UNSPSC 51351908 Norgestrienone is a Commodity code for a specific synthetic progestin pharmaceutical product, but state and local governments procure it primarily as part of broad, multi-source generic pharmaceutical and over-the-counter product agreements rather than as a standalone line item. Recent solicitation activity shows that purchasing entities acquire access to hundreds of pharmaceutical products through cooperative purchasing vehicles, with pricing and product inclusion negotiated at the program level rather than at the individual drug level. The issuing bodies are multistate purchasing alliances and their member government facilities—state departments, counties, cities, school districts, and other local public bodies that participate in centralized pharmaceutical procurement. Vendors responding to these solicitations must be pharmaceutical manufacturers or authorized distributors holding current Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, maintaining relationships with approved wholesalers, and accepting standardized pricing formats and administrative fee structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and July 1, 2026 contract effective date. The solicitation spans participating state and local government facilities in Minnesota and Oregon and requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with all products available by May 15, 2026. Evaluation criteria emphasize price competitiveness at 75 percent weight, with the remaining 25 percent allocated to fixed pricing structure, administrative compliance, EDI capability, and acceptance of a 3 percent administrative fee. Vendors must carry comprehensive insurance including $5 million general liability coverage and comply with performance penalties ranging from $200 to $1,500 per violation. The contract term runs two years for new vendors with optional MMCAP extensions, or through June 30, 2028 for incumbent responders.